Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients.
10.19746/j.cnki.issn.1009-2137.2023.04.020
- Author:
Fang-Shu GUAN
1
;
Dong-Hua HE
1
;
Yi LI
1
;
Yi ZHANG
2
;
Gao-Feng ZHENG
1
;
Yuan-Yuan ZHU
1
;
Jing-Song HE
1
;
En-Fan ZHANG
1
;
Zhen CAI
1
;
Yi ZHAO
3
Author Information
1. Bone Marrow Transplantation Center, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.
2. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.
3. Bone Marrow Transplantation Center, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.E-mail: zhaoyi999@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
CD34;
hematopoietic stem cell mobilization;
lymphoma;
peripheral blood hematopoietic stem cell;
plerixafor
- MeSH:
Humans;
Antigens, CD34/metabolism*;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Hematopoietic Stem Cell Mobilization/methods*;
Hematopoietic Stem Cell Transplantation;
Heterocyclic Compounds/therapeutic use*;
Lymphoma/drug therapy*;
Multiple Myeloma/drug therapy*;
Retrospective Studies;
Transplantation, Autologous
- From:
Journal of Experimental Hematology
2023;31(4):1056-1060
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of plerixafor combined with granulocyte colony-stimulating factor (G-CSF) in mobilizing peripheral blood hematopoietic stem cells in patients with lymphoma.
METHODS:The clinical data of lymphoma patients who received autologous hematopoietic stem cell mobilization using plerixafor combined with G-CSF from January 2019 to December 2021 were retrospectively analyzed. The patients received 3 kinds of mobilization regimens: front-line steady-state mobilization, preemptive intervention, and recuse mobilization. The acquisition success rate, excellent rate of collection, and incidence of treatment-related adverse reaction were counted. The influence of sex, age, disease remission status, bone marrow involvement at diagnosis, chemotherapy lines, number of chemotherapy, platelet count and number of CD34+ cells on the day before acquisition in peripheral blood on the collection results were analyzed to identify the risk factors associated with poor stem cell collection.
RESULTS:A total of 43 patients with lymphoma were enrolled, including 7 cases who received front-line steady-state mobilization, 19 cases who received preemptive intervention, and 17 cases who received recuse mobilization. The overall acquisition success rate was 58.1% (25/43) after use of plerixafor combined with G-CSF, and acquisition success rate of front-line steady-state mobilization, preemptive intervention, and recuse mobilization was 100%, 57.9%(11/19), and 41.2%(7/17), respectively. The excellent rate of collection was 18.6%(8/43). A total of 15 patients experienced mild to moderate treatment-related adverse reactions. The number of CD34+ cells < 5 cells/μl in peripheral blood on the day before collection was an independent risk factor affecting stem cell collection.
CONCLUSIONS:Plerixafor combined with G-CSF is a safe and effective mobilization regimen for patients with lymphoma. The number of CD34+ cells in peripheral blood on the day before collection is an predictable index for the evaluation of stem cell collection.
